Amgen said there is a "strategic and financial rationale" for the US$27.8 billion acquisition with the addition of a "complementary portfolio of medicines from Horizon that address the needs of patients suffering from rare diseases."
Amgen secures significant acquisition of Horizon Therapeutics
December 14, 2022 Latest NewsBioPharma
Latest Video
New Stories
-
Prescription medicines at the centre of Trump’s 'Great Healthcare Plan'
January 18, 2026 - - Latest News -
Boehringer Ingelheim again recognised as a top employer across Australia and New Zealand
January 18, 2026 - - Latest News -
The quiet and steady privatisation of this critical public health program
January 18, 2026 - - Latest News -
AbbVie to consolidate Sydney operations with move to CBD headquarters
January 15, 2026 - - Latest News -
Anne Harris steps down after defining leadership during COVID and lasting impact on Medicines Australia
January 14, 2026 - - Latest News -
AusBiotech joins Trade Diversification Network to boost global life sciences partnerships
January 13, 2026 - - Australian Biotech -
Reread this document - even its redactions reveal that change might be coming
January 13, 2026 - - Latest News

